Bristol Myers Squibb reported third-quarter earnings and revenue that blew past expectations on strong sales from its blood thinner Eliquis and a portfolio of drugs it expects to deliver long-term growth.
The pharmaceutical giant also raised its full-year revenue and adjusted earnings forecast.
The results come as Bristol Myers moves to slash $1.5 billion in costs by the end of 2025 and funnel that money into key drug brands and research and development programs.
